TY - JOUR

T1 - High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies

AU - Vaitkeviciene, G

AU - Forestier, E

AU - Hellebostad, M

AU - Donovan, Martin Heyman

AU - Jonsson, OG

AU - Lähteenmäki, PM

AU - Rosthøj, Susanne

AU - Schmiegelow, K

AU - Söderhäll, S

PY - 2011/1

Y1 - 2011/1

N2 - Prognostic impact of peripheral blood white blood cell count (WBC) at the diagnosis of childhood acutelymphoblastic leukaemia (ALL) was evaluated in a population-based consecutive series of 2666 childrenaged 1–15 treated for ALL between 1992 and 2008 in the five Nordic countries (Denmark, Finland, Iceland,Norway and Sweden). Ten-year event-free (pEFS10y) survival and overall (pOS10y) survival were0.75 ± 0.01 and 0.85 ± 0.01, respectively. Although treatment intensity was determined by WBC, nonremissionand relapsed patients still had significantly higher WBC than those in remission for B-cell precursor(BCP) (median WBC: 24.8 vs. 14.0 vs. 8.3 · 109 / L, P < 0.001), but not for T-lineage (T-ALL) (medianWBC: 127.8 vs. 113.0 vs. 86.8 · 109 / L, P = 0.22). pEFS was inversely related to WBC for BCP(P < 0.001), but not for T-ALL. WBC was not associated with risk of event for BCP or T-ALL for patientswith minimal residual disease at the end of induction (MRDd29) <10)3. In contrast, for MRDd29 ‡ 10)3 and<5% leukaemic blasts in bone marrow at day 29, the pEFS5y for WBC < 100.0 (N = 152) vs. ‡100.0(N = 19) was 0.76 vs. 0.50 (P = 0.001). That was the case both for BCP (pEFS5y 0.76 vs. 0.58) and forT-ALL (pEFS5y 0.71 vs. 0.38). Whether the inferior EFS for the subset of patients with high WBC and slowinitial response to treatment reflects rare or overlooked cytogenetic aberrations as well as the factors thatdetermine WBC levels at diagnosis awaits exploration.

AB - Prognostic impact of peripheral blood white blood cell count (WBC) at the diagnosis of childhood acutelymphoblastic leukaemia (ALL) was evaluated in a population-based consecutive series of 2666 childrenaged 1–15 treated for ALL between 1992 and 2008 in the five Nordic countries (Denmark, Finland, Iceland,Norway and Sweden). Ten-year event-free (pEFS10y) survival and overall (pOS10y) survival were0.75 ± 0.01 and 0.85 ± 0.01, respectively. Although treatment intensity was determined by WBC, nonremissionand relapsed patients still had significantly higher WBC than those in remission for B-cell precursor(BCP) (median WBC: 24.8 vs. 14.0 vs. 8.3 · 109 / L, P < 0.001), but not for T-lineage (T-ALL) (medianWBC: 127.8 vs. 113.0 vs. 86.8 · 109 / L, P = 0.22). pEFS was inversely related to WBC for BCP(P < 0.001), but not for T-ALL. WBC was not associated with risk of event for BCP or T-ALL for patientswith minimal residual disease at the end of induction (MRDd29) <10)3. In contrast, for MRDd29 ‡ 10)3 and<5% leukaemic blasts in bone marrow at day 29, the pEFS5y for WBC < 100.0 (N = 152) vs. ‡100.0(N = 19) was 0.76 vs. 0.50 (P = 0.001). That was the case both for BCP (pEFS5y 0.76 vs. 0.58) and forT-ALL (pEFS5y 0.71 vs. 0.38). Whether the inferior EFS for the subset of patients with high WBC and slowinitial response to treatment reflects rare or overlooked cytogenetic aberrations as well as the factors thatdetermine WBC levels at diagnosis awaits exploration.

U2 - 10.1111/j.1600-0609.2010.01522.x

DO - 10.1111/j.1600-0609.2010.01522.x

M3 - Journal article

C2 - 21077959

VL - 86

SP - 38

EP - 46

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -